EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Radiotherapy meets anticancer metallodrugs

Shuren Zhang, Siyong Shen, Jiangsheng Li, Qunfeng Fu, Zijian Guo, Zhibo Liu iD

Medical Review · 24.04.2026 · 6 (2) · 166-169

DOI: 10.1515/mr-2026-0013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Review, online erschienen am 18.03.2026. Verfasst von Shuren Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Changping Laboratory, Beijing, China. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combined radiotherapy and chemotherapy remain central to cancer treatment, with metallodrugs – most notably platinum agents – playing indispensable roles in clinical regimens. However, systemic toxicity and limited tumor selectivity continue to constrain their optimal integration with radiotherapy. Recent advances in radiation precision and metal chemistry are reshaping this landscape, giving rise to strategies in which radiotherapy and anticancer metallodrugs no longer act merely in combination, but intersect at the molecular level. Ionizing radiation generates highly reactive chemical species that can be harnessed to activate, modulate, or amplify the function of metallodrugs within irradiated tissues. Across platinum prodrugs, non-platinum metal complexes, and high-Z metal materials, radiation energy is increasingly exploited to achieve spatially confined cytotoxicity, immune modulation, and synergistic tumor control. Notably, radiometal-based drugs integrate radiochemistry with metal coordination chemistry, positioning themselves at the intersection of radiotherapy and metallodrug therapy, where they are already playing an increasingly important role in clinical oncology.

Schlagwörter

Stichwörter der Autor:innen

cancer therapychemoradiotherapymetallodrugsprecise medicineradiotherapy

Autor:innen und Institutionen

  • Changping Laboratory, Beijing, China.
  • Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
  • Department of Nuclear Medicine, Key Laboratory of Carcinogenesis and Translational Research of Ministry of Education, Key Laboratory for Research and Evaluation of Radiopharmaceuticals of National Medical Products Admin…
  • Department of Radiology, Molecular Imaging Program at Stanford, Stanford Medicine, Stanford, CA, USA.
  • School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), State Key Laboratory of Coordination Chemistry, Nanjing University, Nanjing, China.
  • Peking University-Tsinghua University Centre for Life Sciences, Peking University, Beijing, China.

ORCID-Profile: Zhibo Liu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, S., Shen, S., Li, J., Fu, Q., Guo, Z., & Liu, Z. (2026). Radiotherapy meets anticancer metallodrugs. Medical Review, 6(2), 166-169. https://doi.org/10.1515/mr-2026-0013

Vancouver

Zhang S, Shen S, Li J, Fu Q, Guo Z, Liu Z. Radiotherapy meets anticancer metallodrugs. Medical Review. 2026;6(2):166-169. doi:10.1515/mr-2026-0013

BibTeX
@article{Zhang2026,
  author = {Zhang, Shuren and Shen, Siyong and Li, Jiangsheng and Fu, Qunfeng and Guo, Zijian and Liu, Zhibo},
  title = {Radiotherapy meets anticancer metallodrugs},
  journal = {Medical Review},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {166--169},
  doi = {10.1515/mr-2026-0013}
}
Kostenlos starten →